Author: Ravi Shankar

Physician-scientist and oncology leader brings more than two decades of experience in academic medicine, global clinical development and regulatory submissions

BRISBANE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the appointment of Arati V. Rao, M.D., as chief medical officer. Dr. Rao brings more than 20 years of experience spanning academic hematology and oncology, early- and late-stage clinical development, and global regulatory submissions. She will lead Nurix’s clinical development organization as the company advances its registrational program for bexobrutideg and its broader pipeline.

“Arati brings deep expertise in hematologic malignancies and a record of leading global development programs from clinical investigation through regulatory submission and approval,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “As we advance bexobrutideg with Roche, her experience will be invaluable in executing our clinical strategy. Arati’s leadership across early- and late-stage development will also help us translate the next generation of Nurix’s scientific advances into potential new medicines for patients.”

“Targeted protein degradation offers a compelling opportunity to develop new treatments for patients whose diseases remain inadequately controlled by existing therapies,” said Dr. Rao. “Nurix has built a strong scientific foundation and a clinical pipeline with the potential to make a meaningful difference in patients’ lives. I look forward to working with the Nurix team, our partners and clinical investigators to advance bexobrutideg and bring additional programs into and through clinical development.”

Dr. Rao joins Nurix from Pfizer, where she served as vice president, late-stage clinical development, and most recently as global franchise head for PF-08634404, a PD-1/VEGF bispecific antibody. At Pfizer, she led global, cross-functional development teams and held leadership roles overseeing thoracic oncology and hematology. Before Pfizer’s acquisition of Seagen, she served as Seagen’s vice president, early-stage clinical development, overseeing a portfolio of antibody-drug conjugates and immunotherapy programs, as well as external collaborations.

Dr. Rao previously served as the clinical development lead for U.S., European and other worldwide regulatory submissions for the CAR T cell therapy Tecartus (brexucabtagene autoleucel) at Kite-Gilead. Her efforts supported its 2020 FDA approval as the first CAR T-cell therapy for adults with relapsed or refractory mantle cell lymphoma.

Before entering industry, Dr. Rao was an associate professor of medicine at Duke University, where she provided patient care and led NIH-funded clinical and translational research in hematologic malignancies. She has served in leadership and committee roles with organizations including the American Society of Hematology, the American Society of Clinical Oncology and the National Comprehensive Cancer Network. Dr. Rao earned her medical degree from B.J. Medical College in Pune, India, and completed her internal medicine residency and fellowships in hematology-oncology and geriatrics at Duke University.

About Nurix Therapeutics
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical-stage oncology pipeline includes bexobrutideg, a degrader of BTK being co-developed with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix’s autoimmune disease pipeline includes bexobrutideg in collaboration with Roche and a clinical-stage degrader of IRAK4 in collaboration with Gilead. Nurix is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates in its wholly owned preclinical pipeline and under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information, visit www.nurixtx.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the expected contributions Dr. Rao will bring to Nurix, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the period ended August 31, 2026, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix’s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix’s stock price. Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

Investors and Media

Kris Fortner
Nurix Therapeutics, Inc.
kfortner@nurixtx.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9b845e3c-523a-4a3c-aca9-75f9ac17557d

BATON ROUGE, La., Nov. 11, 2026 (GLOBE NEWSWIRE) — Lamar Advertising Company (Nasdaq: LAMR) (“Lamar” or the “Company”), a leading owner and operator of outdoor advertising assets, announced today that it has acquired the assets of Newman Outdoor Advertising (“Newman”), bolstering its presence in the Midwest.

The acquisition, which closed this week, adds more than 2250 billboard faces, including 73 digital displays, in North Dakota, Minnesota, Montana and South Dakota.

Newman was founded in North Dakota in 1956 by Harold Newman, who began the business in his mother-in-law’s garage painting signs to pay for college tuition. Over time, the company expanded into the manufacturing of traffic and road safety signs and into large-format printing and established a portfolio of billboard assets in New Mexico. The non-billboard businesses and billboards in the Southwest were previously divested.

“We are thrilled to add Newman’s inventory, which will further strengthen our portfolio across the upper Midwest. The transaction immediately establishes us as the leading player in North Dakota,” said Sean Reilly, Lamar’s chief executive officer. “As a company with deep family roots ourselves, we admire the platform that the Newman family built and we appreciate their trust in Lamar to carry the business forward.”

The purchase price, which was paid in cash, was not disclosed.

“The Newman family wishes Lamar the very best as they take over the Newman Outdoor inventory. This is a good day for our family as I’m confident it is for Lamar,” said Kari Newman Ness, Chairperson of the Board.

Delancey Street Partners acted as financial advisor to Newman, while DeWitt LLP acted as legal advisor. Kean Miller LLP acted as legal advisor to Lamar.

Company Contact:

Buster Kantrow (225) 926-1000 bkantrow@lamar.com

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 11, 2026 (GLOBE NEWSWIRE) — Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will participate in the following upcoming investor conferences and host investor meetings.

2026 Jefferies Global Healthcare Conference
Fireside Chat: Tuesday, November 17, 2026, at 5:00 PM GMT
Location: London, United Kingdom

9^th Annual Evercore Healthcare Conference
Fireside Chat: Tuesday, December 1, 2026, at 3:00 PM ET
Location: Coral Gables, FL

A live webcast of the presentation and fireside chat will be available for replay under “Events & Presentations” section in the Investors section of Hemab Therapeutics’ website at hemab.com.

About Hemab Therapeutics

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an antifibrinolytic targeting plasmin inhibition in clinical development for heavy menstrual bleeding.

Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.

Media:
Deerfield
Peg Rusconi
peg.rusconi@deerfieldgroup.com

Investors:
Hemab Therapeutics
Mads Behrndt
investors@hemab.com

A Fresh Way to Experience Breckenridge Distillery Through Special Bottlings, Tastings and Behind-The-Scenes Access

BRECKENRIDGE, Colo., Nov. 11, 2026 (GLOBE NEWSWIRE) — Breckenridge Distillery, one of the most awarded craft distilleries in the U.S. and a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), today announced the launch of the 2 Mile High Whiskey Club, a new membership that delivers limited releases, special cask finishes and single-barrel picks straight to members, along with an insider’s view of the people and process behind them. Some of Breckenridge Distillery’s best whiskeys never make it to store shelves, and the club gives whiskey lovers a way in.

Membership is $199 per quarter and includes two 750mL bottles each season, chosen from a rotating mix of the distillery’s most distinctive whiskeys. Spots are limited, with more opening each quarter. Membership is open to adults 21+. To join, visit https://club.breckenridgedistillery.com/.

What members get:

• Two exclusive bottles every quarter: Limited releases, special cask finishes, single-barrel offerings and other hard-to-find Breckenridge whiskeys.
• Virtual tastings and cocktail sessions: Built around each release, covering the flavors, techniques and inspiration behind every bottle.
• Insider updates: Distillery news, seasonal cocktail recipes and first word on upcoming releases and projects in development.
• Preferred access: Access to distillery events.
• Member discounts: 10% off at the Breckenridge Distillery Restaurant and 15% off merchandise and bottles in-store at the Breckenridge Distillery’s two retail stores.

The first lineup shows the range of what’s happening in Breckenridge’s barrels. Planned selections include Breckenridge Holiday Blend, a Merlot Cask Finish Whiskey and a Master Distiller’s pick of Breckenridge Powder Hound Whiskey.

“There’s always something new happening in our barrels, and some of our most exciting whiskeys are the ones you can’t find everywhere,” said Bryan Nolt, Founder and CEO of Breckenridge Distillery. “The 2 Mile High Whiskey Club is our way of sharing those discoveries with people who really love whiskey and giving them a front-row seat to what we’re creating along the way.”

The club is just getting started. Future programming may include private tastings, whiskey education sessions and the chance for members to help select a club single barrel, giving them a hands-on role in the distillery’s whiskey-making process.

Ready to join? Visit https://club.breckenridgedistillery.com/ to reserve a spot before this quarter’s memberships are claimed.

Age 21+. Always enjoy responsibly.

About Breckenridge Distillery

Founded in Colorado in 2008, Breckenridge Distillery is the “World’s Highest Distillery,” and is best known for its award-winning blended bourbon whiskey, a high-rye mash American-style whiskey. One of the most highly awarded distilleries in the U.S., the Breckenridge Distillery is proudly a 3x Icons of Whisky and 10x winner of Best American Blended at the World Whiskies Awards by Whisky Magazine and a 6x winner of Colorado Distillery of the Year by the New York International Spirits Competition. Most recently, Breckenridge Port Cask Finish was named World’s Best Finished Bourbon at the 2024 World Whiskies Awards, joining Breckenridge High Proof, named World’s Best Blended Whiskey, and Breckenridge Gin, named World’s Best Compound Gin at the World Gin Awards by Gin Magazine. Breckenridge spirits have been awarded 7 Double Golds at the San Francisco World Spirits Competition.

The Breckenridge Distillery is more than award-winning spirits, offering an immersive guest experience. Named one of the country’s Top Visitor Attractions by Whisky Magazine, guests can dine at the award-winning restaurant, enjoy show-stopping cocktails, explore an in-depth tasting, and get an inside look at the active production facility—including the opportunity to blend their own whiskey.

Breckenridge Distillery is a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life.

To learn more about Breckenridge Distillery, visit www.breckenridgedistillery.com. Keep up with Breckenridge Distillery on Instagram by following @breckdistillery and become a fan at facebook.com/BreckDistillery. For more information about Tilray Brands, visit www.tilray.com and follow @tilray on Instagram, Twitter, Facebook, and LinkedIn.

About Tilray Brands 
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages. 

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms. 

Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

For further information, please contact
Media: Breckenridge@klgpr.com, 970-771-3662
Tilray Brands Media: news@tilray.com
Investors: investors@tilray.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/122d808e-68b5-4d74-aa73-590af46ede5f

https://www.globenewswire.com/NewsRoom/AttachmentNg/1878af09-8fef-4844-bb23-418b278825d0

Expected to add approximately 280 million gallons of annual fuel volume across approximately 400 wholesale locations, expand APC’s Great Lakes infrastructure and vertical integration, and enhance Discretionary Cash Flow

Transaction Highlights:

• Acquisition expected to contribute approximately $30 million of annualized Adjusted EBITDA and enhance Discretionary Cash Flow.
• Expected to increase annual fuel volumes by approximately 14%¹, with approximately 400 additional wholesale locations, expanding APC’s wholesale network to approximately 2,500 locations.
• Enhances vertical integration by adding a Great Lakes infrastructure platform with strategically located fuel terminals in Novi, Michigan and Toledo, Ohio, together with expanded transportation capabilities.
• Advances APC’s strategy to expand its predominantly fixed-margin and fee-based earnings profile while enhancing cash-flow generation.

RICHMOND, Va., Nov. 11, 2026 (GLOBE NEWSWIRE) — ARKO Petroleum Corp. (Nasdaq: APC) (“APC” or the “Company”), one of the largest wholesale fuel distributors in North America, today announced that on November 10, 2026, it completed its previously announced acquisition of the business of U.S. Petroleum Partners, LLC (“USPP”), a vertically integrated fuel supply and distribution platform serving customers throughout the Great Lakes region.

The acquisition is expected to add approximately 280 million gallons of annual fuel volume across approximately 400 wholesale locations, representing an approximately 14%¹ increase in APC’s trailing twelve-month fuel volumes. The acquired assets include two strategically located fuel terminals in Novi, Michigan and Toledo, Ohio connected to the Buckeye Pipeline system, as well as a fleet of vehicles that transport more than 80% of USPP’s distributed fuel volumes.

“The closing of the USPP acquisition represents a meaningful step-up in APC’s scale, earnings power and long-term growth profile,” said Arie Kotler, Chairman, President and Chief Executive Officer of ARKO Petroleum Corp. “The acquisition adds approximately 280 million gallons of annual fuel volume. USPP’s scale and infrastructure expand our presence across the fuel value chain, strengthen our predominantly fixed-margin and fee-based business model and create opportunities to increase terminal utilization, improve transportation efficiency and capture additional margin. We also look forward to working with the USPP team to evaluate additional growth opportunities within their existing acquisition pipeline as we continue to expand APC’s platform. We are pleased to welcome the USPP team to APC, and we look forward to building on the strong platform they have created.”

Kotler continued, “This transaction demonstrates the disciplined acquisition strategy we outlined at the time of our IPO and how we are putting APC’s financial flexibility to work. We expect the acquired business to contribute approximately $30 million of annualized Adjusted EBITDA, enhance APC’s Discretionary Cash Flow generation and strengthen our ability to fund growth, support our dividend and create long-term shareholder value.”

At closing, APC paid approximately $200 million in cash, plus the value of inventory, and issued to the sellers approximately 2.0 million shares of APC Class A common stock, valued at approximately $30 million², to be held in escrow. The number of shares eligible for release to the sellers from escrow, together with dividends earned thereon, is subject to adjustment based on the acquired business achieving certain EBITDA-based financial targets for the 12-month period ending December 31, 2027, and the amount payable may increase (payable in cash or shares of Class A common stock, at the Company’s election), based on the acquired business achieving results greater than such financial targets. The cash portion of the purchase price paid at closing was funded through borrowings under APC’s existing lines of credit. Pro forma for the USPP acquisition, APC’s Net Debt to Adjusted EBITDA is expected to be in the range of 3.0x to 3.5x, which remains within the Company’s previously communicated leverage range of 3.0x to 4.0x and reflects APC’s disciplined approach to capital allocation.

Strategic and Financial Benefits

• Increasing scale. Adds approximately 280 million gallons of annual fuel volume across approximately 400 wholesale locations.
• Expanding geographic presence. Broadens APC’s operations throughout Michigan, Ohio and the Great Lakes region.
• Strengthening fuel supplier relationships. Deepens relationships with major fuel suppliers through increased commercial and operational scale and throughput.
• Diversifying earnings. Adds fuel terminals, which are strategic, long-lived infrastructure assets with meaningful intrinsic value. Located on the Buckeye Pipeline, the terminals enhance vertical integration across the refined product infrastructure value chain, support durable throughput, create an incremental fee-based earnings stream, expand APC’s service footprint across the Great Lakes region and provide multiple avenues for potential earnings growth.
• Supporting cash flow growth. The acquired business is expected to contribute approximately $30 million of annualized Adjusted EBITDA and enhance Discretionary Cash Flow.
• Creating a platform for further growth. Provides opportunities to increase throughput and capture operational efficiencies.

About ARKO Petroleum Corp.

ARKO Petroleum Corp. (Nasdaq: APC) is a growth-oriented fuel distribution company and one of the largest wholesale fuel distributors in North America, supplying approximately 2.2 billion gallons of fuel annually to customers in approximately 3,900 locations in the District of Columbia and more than 30 states across the Mid-Atlantic, Midwestern, Northeastern, Southeastern and Southwestern United States. The Company is engaged in (i) wholesale activity, which includes the supply of fuel to gas stations operated by third-party dealers, (ii) fleet fueling, which includes the operation of proprietary and third-party cardlock locations (unstaffed fueling locations) and the issuance of proprietary fuel cards that provide customers access to a nationwide network of fueling sites, and (iii) the wholesale distribution of fuel to substantially all of the retail convenience stores that sell fuel operated by ARKO Corp., its parent company (Nasdaq: ARKO), one of the largest operators of convenience stores in the United States. The Company’s operations also include two fuel terminals. To learn more about APC, visit www.arkopetroleum.com.

Forward-Looking Statements

This document includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may address, among other things, the Company’s expected financial and operational results and the related assumptions underlying its expected results. These forward-looking statements are distinguished by use of words such as “accretive,” “anticipate,” “aim,” “believe,” “continue,” “could,” “estimate,” “expect,” “guidance,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and the negative of these terms, and similar references to future periods. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations due to, among other things, changes in economic, business and market conditions; the Company’s ability to successfully integrate businesses that it acquires, including the business of USPP; the Company’s ability to achieve the benefits that it expects to realize as a result of its acquisitions, including the business of USPP; the potential negative impact on the Company’s financial condition and results of operations if it fails to achieve the benefits that it expects to realize as a result of its business acquisitions, including the business of USPP; liabilities of acquired businesses that are not known to the Company; the Company’s ability to maintain the listing of its Class A common stock on the Nasdaq Stock Market; changes in its strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; expansion plans and opportunities; changes in the markets in which it competes; changes in applicable laws or regulations, including those relating to environmental matters; market conditions and global and economic factors beyond its control; the success of ARKO Corp.’s transformation plan and its effect on the Company, including the dealerization of retail stores; and the outcome of any known or unknown litigation and regulatory proceedings. Detailed information about these factors and additional important factors can be found in the documents that the Company files with the Securities and Exchange Commission, such as Form 10-K, Form 10-Q and Form 8-K. Forward-looking statements speak only as of the date the statements were made. The Company does not undertake an obligation to update forward-looking information, except to the extent required by applicable law.

Use of Non-GAAP Measures

The Company defines EBITDA as net income before net interest expense, income taxes, depreciation and amortization. Adjusted EBITDA further adjusts EBITDA by excluding the gain or loss on disposal of assets, impairment charges, acquisition costs, share-based compensation expense, other non-cash items, and other unusual or non-recurring charges. Both EBITDA and Adjusted EBITDA are non-GAAP financial measures. Neither these measures nor those described below should be considered an alternative to measurements presented in accordance with generally accepted accounting principles in the United States (“GAAP”).

The Company uses EBITDA and Adjusted EBITDA for operational and financial decision-making and believes these measures are useful in evaluating its performance because they eliminate certain items that it does not consider indicators of its operating performance. EBITDA and Adjusted EBITDA are also used by many of its investors, securities analysts and other interested parties in evaluating its operational and financial performance across reporting periods. The Company believes that the presentation of EBITDA and Adjusted EBITDA provides useful information to investors by allowing an understanding of key measures that it uses internally for operational decision-making, budgeting, evaluating acquisition targets, and assessing its operating performance.

The Company defines Net Debt as the sum of total debt, net, financing leases and financial liabilities, less cash and cash equivalents. Net Debt is used by management to measure the effective level of our indebtedness.

The Company defines the Ratio of Net Debt to Adjusted EBITDA as the ratio derived by dividing Net Debt by Adjusted EBITDA. The Ratio of Net Debt to Adjusted EBITDA is an important measure used by management to evaluate the Company’s access to liquidity, and the Company believes it provides useful information for investors as a representation of its financial strength by presenting the sustainability of its debt levels and its ability to take on additional debt against Adjusted EBITDA, which is used as an operating performance measure. The Ratio of Net Debt to Adjusted EBITDA is also frequently used by investors and credit rating agencies to analyze the Company’s operating performance.

The Company defines Discretionary Cash Flow as net cash provided by operating activities, (i) less changes in operating assets and liabilities, maintenance capital expenditures, charges to allowance for credit losses, and non-cash rent expense, and (ii) plus acquisition costs, amortization of deferred income net of prepaid to related party, and certain other expenses (income). Discretionary Cash Flow will not reflect changes in working capital balances. Discretionary Cash Flow is a liquidity measure the Company and third parties, such as industry analysts, investors, lenders, rating agencies and others, use to assess its ability to internally fund acquisitions, pay dividends, and service or incur additional debt. The Company believes that the presentation of Discretionary Cash Flow provides useful information to investors, securities analysts, and other interested parties for evaluating its liquidity.

EBITDA, Adjusted EBITDA, Net Debt, the Ratio of Net Debt to Adjusted EBITDA and Discretionary Cash Flow should not be considered as alternatives to any financial measure presented in accordance with GAAP, including net income and net cash provided by operating activities. These non-GAAP measures have limitations as analytical tools and should not be considered in isolation, or as substitutes for the analysis of results as reported under GAAP. The Company strongly encourages investors to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

Because non-GAAP financial measures are not standardized, these measures as defined by the Company may not be comparable to similarly titled measures reported by other companies. It therefore may not be possible to compare the Company’s use of these non-GAAP financial measures with those used by other companies.

Reconciliations of forward-looking non-GAAP measures included in this press release to the corresponding GAAP financial measures are not included due to variability and difficulty in making accurate forecasts and projections, particularly in light of potential changes in USPP’s business following its acquisition, and because certain information is not currently ascertainable or accessible, and because not all of the information necessary for a quantitative reconciliation of these forward-looking non-GAAP financial measures is available to the Company without unreasonable efforts. For the same reasons, the Company is unable to address the probable significance of the unavailable information, nor can the Company accurately predict all the components of the applicable non-GAAP financial measures and reconciling adjustments thereto; accordingly, the corresponding GAAP measures may be materially different than the non-GAAP measures. Such forward-looking information is also subject to uncertainty and various risks, including those set forth in the risk factors discussed above, and there can be no assurance that any forecasted results or conditions will actually be achieved.

Company and Investor Contact

Priya Trivedi
ARKO Petroleum Corp.
investors@arkopetroleum.com

---

¹ Based on APC’s total gallons distributed for the twelve-month period ended September 30, 2026. 
² Based on daily volume weighted average price of APC Class A common stock for the ten consecutive trading days immediately preceding the closing date.

KELLOGG, Idaho, Nov. 11, 2026 (GLOBE NEWSWIRE) — Bunker Hill Silver Corp. (“Bunker Hill” or the “Company”) (TSX: BNKR | OTCQB: BHLL) is announcing that Mr. Gary Thompson has resigned from the board of directors of the Company (the “Board”), effective November 10, 2026. Mr. Thompson’s resignation, mutually agreed, supports Mr. Thompson’s need to balance his other commitments and the Company’s goal to maintain an appropriate mix of independent and executive directors on its Board, in connection with ongoing preparations for a potential listing of the Company’s shares on a U.S. national securities exchange.

Mr. Thompson, who played a key role in advancing the arrangement (the “Arrangement”) between the Company and Silver47 Exploration Corp. (“Silver47”) was appointed to the Board on completion of the Arrangement. Prior to serving on the Board, Mr. Thompson served as Executive Director of Silver47 since its inception in 2021, now a wholly owned subsidiary of Bunker Hill. Mr. Thompson’s decision was not the result of any disagreement with the Company on any matter.

Richard Williams, Bunker Hill Executive Chairman, stated: “On behalf of the Bunker Board and management, I want to thank Gary for everything he has contributed to bringing the transaction with Silver47 to a successful close, and for engaging constructively with the Board as we prepare for a potential future US listing. We wish him all the best with his current and future assignments.”

In furtherance of the Company’s commitment to strong corporate governance, and as the Company continues to pursue a listing on a U.S. national securities exchange, the Governance and Nominations Committee of the Board has commenced a search for an additional two independent directors and expects to make an appointment in the coming months. There is no guarantee that the Company’s shares will be listed on a U.S. national exchange.

ABOUT BUNKER HILL SILVER CORP.

Bunker Hill Silver Corp. is a U.S.-focused mining company building a modern, long-life operation at its flagship Bunker Hill Mine in northern Idaho’s prolific Silver Valley, complemented by a pipeline of high-grade silver development projects across North America. With production now underway, the Company is advancing the Bunker Hill Mine toward commercial production of zinc, lead and silver concentrates while pursuing opportunities to optimize operations, expand resources and extend mine life.

The Bunker Hill Mine sits in one of North America’s most abundant and storied mining districts and benefits from established infrastructure, a skilled local workforce and a significant mineral resource base. Through its acquisition of Silver47 Exploration Corp., Bunker Hill has added a portfolio of silver-rich projects in Alaska, Nevada and New Mexico, anchoring the Company in America’s most prolific mining jurisdictions.

Bunker Hill’s strategy is focused on disciplined operational execution, responsible mining practices and continued investment in its assets to deliver sustainable production, organic growth and long-term shareholder value.

Additional information is available www.bunkerhillsilver.com, on SEDAR+ and on EDGAR.

For additional information, please contact:
Giordy Belfiore
Vice President, Investor Relations
T: (604) 288-8004
E: IR@bunkerhillmining.com

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this news release are forward-looking and involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, as well as within the meaning of the phrase “forward-looking information” in the Canadian Securities Administrators’ National Instrument 51-102 – Continuous Disclosure Obligations (collectively, “forward-looking statements”). Forward-looking statements are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, “plan” or variations of such words and phrases.

Forward-looking statements in this news release include, but are not limited to, statements regarding: the potential appointment of a new director or directors, a potential future listing of the Company’s shares on a U.S. national securities exchange and the likelihood or ability to qualify for such listing, the Company’s general objectives, goals or future plans, and any similar statements. Forward-looking statements reflect material expectations and assumptions, including, without limitation, expectations and assumptions relating to: sufficiency of project financing for the ramp up of commercial production of the Bunker Hill Mine on acceptable terms or at all; the future price of metals; and the stability of the financial and capital markets. Factors that could cause actual results to differ materially from such forward-looking statements include, but are not limited to, those risks and uncertainties identified in public filings made by Bunker Hill with the U.S. Securities and Exchange Commission (the “SEC”) and with applicable Canadian securities regulatory authorities, including its latest annual report on Form 10-K as filed with the SEC on March 6, 2026, and the following: the Company’s inability to raise additional capital for project activities, including through equity financings, concentrate offtake financings or otherwise; capital market conditions; failure to identify mineral resources; failure to convert estimated mineral resources to reserves; the preliminary nature of metallurgical test results; the Company’s ability to ramp up the Bunker Hill Mine to commercial production and the risks of not basing a production decision on a feasibility study of mineral reserves demonstrating economic and technical viability . Although the Company believes that the assumptions and factors used in preparing the forward-looking statements in this news release are reasonable, undue reliance should not be placed on such statements or information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Readers are cautioned that the foregoing risks and uncertainties are not exhaustive. Additional information on these and other risk factors that could affect the Company’s operations or financial results are included in the Company’s annual report and may be accessed through the SEDAR+ website (www.sedarplus.ca) or through EDGAR on the SEC website (www.sec.gov).

• No cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), or graft-versus-host disease (GvHD) across 40 patients treated across five indications in the Ntrust program.
• No deaths and no treatment discontinuations due to adverse events.
• Grade 3 or higher treatment-emergent adverse events were primarily hematologic and attributed to lymphodepletion.
• Five patients (12.5%) had infusion-related reactions deemed associated with NKX019; all resolved within 24-48 hours and without tocilizumab.
• No increase in adverse events was observed at higher doses.

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced integrated safety results from 40 patients treated with NKX019, an allogeneic, off-the-shelf, CD19-directed CAR NK cell therapy candidate in its ongoing Ntrust clinical trial program.

The findings were presented today in an oral presentation at the American College of Rheumatology (ACR) Convergence 2026 in Orlando by Guillermo J. Valenzuela, M.D., of Integral Rheumatology and Immunology Specialists in Plantation, Florida. The data cutoff was September 18, 2026. The cumulative safety analysis included patients with systemic sclerosis, myositis, lupus nephritis, rheumatoid arthritis, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

There were no deaths and no treatment discontinuations due to adverse events. There were no reported cases of CRS of any grade, ICANS, IEC-HS or GvHD. No cases of leukoencephalopathy, a neurotoxicity associated with fludarabine, have been reported to date.

“The absence of CRS, ICANS, IEC-HS and GvHD across 40 patients and five autoimmune diseases reinforces our belief that CAR NK cells could offer a differentiated approach to autoimmune cell therapy,” said Paul J. Hastings, Chief Executive Officer of Nkarta. “Unlike CAR T cells, which can undergo rapid and substantial expansion in the body, NKX019 is designed to deliver targeted B-cell depletion with limited in vivo expansion and more predictable cellular exposure. These fundamental biological differences may allow us to achieve the therapeutic benefits of CD19-directed cell therapy without the toxicities associated with autologous T cell-based modalities.”

Integrated Safety Results 

The integrated analysis included 40 patients enrolled in the Ntrust Phase 1/2 clinical trials. Patients had active or progressive disease despite previous use of standard-of-care therapies, with 30 patients (75%) receiving four or more prior treatments. Median disease duration was 4.7 years (range 0.3 to 30.7).

Patients received outpatient lymphodepleting preconditioning with fludarabine and cyclophosphamide, followed by a three-dose cycle of NKX019 at 1 billion, 2 billion or 4 billion cells per dose. Twenty-eight patients (70%) received the 4 billion cell dose, seven (17.5%) the 2 billion cell dose and five (12.5%) the 1 billion cell dose. Treatment-emergent adverse events were defined as adverse events occurring from the start of lymphodepletion through 30 days after the last NKX019 dose, regardless of causality.

Key findings from the integrated safety analysis included:

• No immune effector cell-associated toxicities or GvHD: No cases of CRS, ICANS, IEC-HS or GvHD were reported across all 40 patients and five disease indications.
• No deaths or treatment discontinuations: No deaths and no treatment-emergent adverse events leading to treatment discontinuation were reported.
• Grade 3 or higher adverse events predominantly hematologic: Treatment-emergent adverse events occurred in 34 patients (85%), including grade 3 or higher events in 14 (35%), most commonly hematologic and typically attributed to lymphodepletion. Hematologic changes generally recovered within one to two months; grade 3 or higher cytopenias lasting more than 28 days in five patients (12.5%).
• Infusion-related reactions: Five patients (12.5%) had infusion-related reactions associated with NKX019: four were grade 1 and one was grade 3. All resolved within 24 to 48 hours with standard supportive care, without the use of tocilizumab.
• Consistent tolerability across dosing cohorts: No increase in adverse event frequency was observed across the 1 billion (n=5), 2 billion (n=7) or 4 billion cell (n=28) dose levels.

NKX019 is manufactured from healthy donor-derived NK cells and cryopreserved for delivery to clinical sites. It does not require patient leukapheresis or individualized manufacturing.

“For patients living with refractory autoimmune diseases, the burden is progressive disability, pain and the uncertainty of whether the next treatment will work after so many others have failed,” said Dr. Valenzuela. “Cell therapy offers new hope, but access is currently constrained by where patients live and whether they can access a highly specialized treatment center. If we can deliver the therapeutic potential of CD19-directed cell therapy with a manageable safety profile, patients could receive these treatments in their own communities from rheumatologists who know them. That would represent a sea change in autoimmune care.”

About the Ntrust℠ Clinical Trials in Autoimmune Disease
Ntrust-1 (NCT06557265) and Ntrust-2 (NCT06733935) are multi-center, open-label, dose-escalation clinical trials in patients with autoimmune disease receiving lymphodepletion followed by CD19-targeted CAR NK cell therapy. Both trials assess the safety of NKX019 in people living with autoimmune diseases as well as its potential to achieve durable remission via a “reset” of the immune system through the elimination of pathogenic B cells.

The Ntrust trials are enrolling up to 12 patients per dose level per disease indication. Additional patients may be enrolled if needed to refine patient populations for further study.

In both studies, patients receive a three-dose cycle of NKX019 following lymphodepleting preconditioning with fludarabine and cyclophosphamide or cyclophosphamide alone, if they have significant cytopenia at baseline. This approach is designed to evaluate the single-agent activity of NKX019 and facilitate a more rapid path to regulatory approval. Patients in both trials may also receive additional cycles, if needed, to restore response or enable a deeper response.

About NKX019
NKX019 is an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed chimeric antigen receptor (CAR) for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease. Nkarta is evaluating NKX019 in multiple autoimmune conditions.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for people living with autoimmune diseases. By harnessing the power of the innate immune system to eliminate pathogenic B cells driving the autoimmune response, Nkarta is advancing novel cell therapies engineered for deep therapeutic impact. The on-demand availability and outpatient dosing of our CAR NK cells enable a broad population of patients with different autoimmune conditions to conveniently access NK cell therapy in community health settings. For more information, please visit the company’s website at www.nkartatx.com.

Cautionary Note on Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “potential,” “projects,” “would” and “future” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include, but are not limited to, statements concerning Nkarta’s expectations regarding any or all of the following: Nkarta’s position, plans, strategies and timelines for the continued and future clinical development and potential of NKX019 (including the future availability and disclosure of clinical data and other updates from Nkarta’s clinical trials); the potential differentiation of NKX019 and CAR NK cell therapy from other cell therapy modalities; and the therapeutic potential, accessibility and tolerability of NKX019 for the treatment of autoimmune diseases, including as a result of advancing Nkarta’s dose escalation and expansion of outpatient dosing in community-based settings.

Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Nkarta’s limited operating history and historical losses; Nkarta’s lack of any products approved for sale and its ability to achieve profitability; the risk that the results of preclinical studies and early-stage clinical trials may not be predictive of future results; the risk that initial, interim or preliminary data from Nkarta’s clinical trials, including the data presented at ACR Convergence 2026, reflect a limited number of patients with limited follow-up, may change as more patient data become available and may not be predictive of future results; Nkarta’s ability to raise additional funding to complete the development and any commercialization of its product candidates; Nkarta’s dependence on the clinical success of NKX019, including in its lead indications of myositis and systemic sclerosis; risks associated with outpatient administration of NKX019 at community-based sites; that Nkarta may be delayed in initiating, enrolling patients in or completing its clinical trials; competition from third parties that are developing products for similar uses; Nkarta’s ability to obtain, maintain and protect its intellectual property; Nkarta’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; and the complexity of the manufacturing process for CAR NK cell therapies.

The data described in this press release are preliminary, are from a small number of patients with limited follow-up and may change as additional data become available. No head-to-head studies have been conducted comparing NKX019 with other therapies, and caution should be exercised in drawing conclusions from comparisons of data across separate trials, which may differ in design, patient populations and other factors.

These and other risks and uncertainties are described more fully in Nkarta’s filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of Nkarta’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 5, 2026, and Nkarta’s other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Nkarta undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Nkarta Media/Investor Contact:
Nadir Mahmood
Nkarta, Inc.
nmahmood@nkartatx.com

First state certification advances WRAP’s planned transition from device sales to recurring training programs, supporting a scalable hybrid model combining WrapTactics™ digital learning, in-person proficiency and credentialing

MIAMI, Nov. 11, 2026 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (Nasdaq: WRAP) (“WRAP,” the “Company” or “we”) today announced that the Illinois Law Enforcement Training and Standards Board (ILETSB) has certified the Company’s ten-hour BolaWrap® 150 CIT Rescue Tool Level 1 Law Enforcement User Course for in-service training, recognizing 5.5 hours across five categories of mandated law enforcement training.

We believe this certification represents an important milestone in WRAP’s strategic transition from selling individual devices to delivering operationalized de-escalation as an integrated program, supported by doctrine, standardized curriculum, digital learning, credentialed instructors and ongoing officer proficiency.

Illinois is the first state to recognize a curriculum developed under the WRAP Non-Lethal System Doctrine, the Company’s governing framework for delivering non-lethal response as a professional law enforcement capability.

We believe the progression reflects a central element of WRAP’s commercial strategy: establish the doctrine, translate that doctrine into a standardized curriculum, secure recognition within state training frameworks, and enable agencies to institutionalize the capability within their officers’ continuing professional development.

The curriculum also incorporates WRAP’s WrapTactics™ Learning Management System (LMS) as a digital delivery pathway, allowing participating agencies to complete two hours of standardized foundational instruction online before attending the required in-person portion of the course.

WRAP believes this hybrid digital and physical training architecture can help support scalable program adoption, expand the Company’s recurring training and credentialing opportunities, and strengthen long-term relationships with law enforcement customers.

State Recognition Connects WRAP’s Program to Existing Officer Training Requirements

The Illinois certification recognizes 5.5 hours of WRAP’s ten-hour curriculum across five mandated in-service training categories:

• 2.5 hours: De-escalation Techniques and Role Play
• 1.5 hours: Officer Safety Techniques
• 0.5 hours: De-Escalation
• 0.5 hours: De-Escalation Techniques
• 0.5 hours: Laws Concerning Stops, Searches and Use of Force

By crediting portions of the curriculum toward existing professional training requirements, Illinois provides participating agencies with an opportunity to integrate WRAP’s non-lethal response program into established officer development and continuing education structures.

Rather than treating BolaWrap instruction solely as an additional product-specific training requirement, departments can incorporate recognized portions of the curriculum into their broader mandated training programs, subject to applicable state and agency requirements.

WRAP believes this alignment strengthens product-market fit by connecting its technology and training directly to established professional obligations, creating value beyond the initial equipment purchase.

From Doctrine to Curriculum to State Recognition

The Company believes WRAP’s Non-Lethal System Doctrine advances the Company’s framework for operationalizing de-escalation, providing officers with a structured methodology for assessing resistance, identifying lawful response options, making deployment decisions, transitioning to control and custody, and maintaining accountability throughout an encounter.

From that doctrine, WRAP has developed a standardized curriculum designed to convert operational principles into measurable officer proficiency.

Illinois’ certification marks the first state-level recognition of that curriculum and, the Company believes, illustrates how elements of WRAP’s doctrine-derived training can align with formal state-mandated law enforcement education requirements.

“We are fundamentally changing what WRAP delivers to law enforcement,” said Jared Novick, President of WRAP Technologies. “We are moving from selling devices to delivering operationalized de-escalation as a complete program. That starts with doctrine. From doctrine comes standardized curriculum, and from curriculum comes credentialing, proficiency and institutional adoption. Illinois is the first state to recognize that curriculum within its mandated training framework, and that is an important validation of the direction we are taking.”

Novick continued, “When officers can receive credit toward their existing professional training requirements while developing proficiency in our non-lethal response system, we believe we create value that extends well beyond the initial purchase of a device. By combining scalable digital instruction with hands-on certification and ongoing proficiency, we believe we have an opportunity to become part of an agency’s recurring readiness and professional development. We believe that is how we deepen customer relationships and build a more durable, recurring business model.”

WrapTactics™ Enables a Scalable Hybrid Digital and In-Person Training Model

A central component of WRAP’s evolving business model is the integration of its WrapTactics™ Learning Management System with traditional instructor-led training and practical proficiency validation.

Under the Illinois-certified curriculum, the first two hours of foundational instruction may be completed digitally before officers arrive for resident training. Alternatively, agencies may elect to deliver those modules in a classroom, with the same learning objectives and assessment requirements.

The remaining eight hours are delivered in person and include equipment handling, decision-making exercises, practical techniques, scenario-based instruction and certification testing.

This approach combines the scalability and consistency of digital learning with the hands-on validation necessary for field readiness.

Through WrapTactics™, WRAP intends to provide a common instructional foundation that can be delivered to officers across multiple agencies and geographic locations without requiring every element of the training program to be repeated in a traditional classroom.

Participating agencies can then build on that instruction through authorized instructors who conduct practical training, assess officer performance and support completion of the required certification process.

The hybrid architecture is designed to support three complementary business objectives:

1. Scalable instruction: Deliver consistent foundational education digitally to larger populations of officers without a proportional increase in classroom resources.
2. Repeatable implementation: Combine digital coursework with credentialed, in-person instruction and proficiency validation to support agency adoption.
3. Recurring customer engagement: Establish opportunities for ongoing learning, refresher education, instructor credentialing and proficiency management throughout an agency’s relationship with WRAP.

The Company believes this model can support a transition from primarily point-in-time equipment transactions toward longer-duration customer relationships built around recurring training, digital learning and operational readiness.

Building Recurring Value Through Professional Readiness

WRAP’s Level 1 curriculum is designed to teach the BolaWrap 150 as part of a complete de-escalation and subject-control methodology rather than as a standalone piece of equipment.

Officers are trained to assess conditions, communicate effectively, determine whether intervention is appropriate, make lawful deployment decisions and transition to custody and care.

Importantly, the curriculum evaluates the decision not to deploy on the same footing as the decision to deploy.

The program incorporates written examinations, practical skills assessments and scenario-based evaluations emphasizing demonstrated proficiency rather than attendance alone.

The certified course is the first of four WRAP credential levels. WRAP’s separate instructor credentialing and recertification framework is intended to support continuing instructional proficiency, while authorized training units and participating agencies remain responsible for delivery under applicable state requirements.

This structure is designed to enable agencies to develop and sustain the capability internally while maintaining an ongoing relationship with WRAP through its training infrastructure, instructional standards and credentialing programs.

For the Company, the distinction is important: the objective is not simply to place additional equipment into departments, but to establish a capability that becomes part of how officers are trained, evaluated and prepared throughout their careers.

Expanding a Repeatable Model Across States

Illinois represents the first step in WRAP’s broader effort to achieve recognition of its doctrine-based curriculum within additional state training systems.

The Company has submitted curriculum materials for consideration in several other states and intends to continue pursuing certification through each jurisdiction’s established review process.

“Every state defines its own training requirements, but the need for officers to make sound decisions under pressure is universal,” said John Chapman, Vice President of Training and Missions of WRAP. “Our goal is to create a system that agencies can adopt and sustain, with standardized digital instruction, qualified instructors and practical proficiency requirements. Illinois demonstrates how a comprehensive non-lethal response curriculum can fit within the professional training structures agencies already use.”

WRAP believes the recognition of its curriculum within established state training requirements is a meaningful indicator of progress in its program-based commercial strategy.

As WRAP advances additional state submissions, expands its WrapTactics™ digital learning capabilities and develops its instructor credentialing network, the Company intends to make operationalized de-escalation a sustained component of agency readiness rather than a one-time equipment acquisition.

The Company believes this approach can create opportunities for broader adoption, more consistent officer proficiency and expanded recurring revenue streams while deepening its relationships with law enforcement customers.

WRAP’s long-term objective is to deliver not simply the technology officers carry, but the doctrine, digital education, hands-on training and ongoing proficiency that support how officers respond.

About WRAP Technologies, Inc.

WRAP Technologies, Inc. (NASDAQ: WRAP) is a public safety technology company developing Non-Lethal Response solutions and emerging security technologies. Through its integrated products, training, services and strategic technology initiatives, WRAP is committed to Operationalizing De-Escalation and expanding capabilities for public safety and national-security professionals.

Trademark Information

WRAP, the Wrap logo, BolaWrap®, Non-Lethal Response™, WrapReality™, WrapShield™, WrapTactics™, Wraptor MX™ and Wrap Training Academy are trademarks of WRAP Technologies, Inc., some of which are registered in the U.S. and abroad. All other trade names used herein are either trademarks or registered trademarks of their respective holders.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “would,” “could,” “intend,” “plan,” “seek,” “continue,” “designed to,” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements include, among others, statements regarding the Company’s strategy to transition from device sales toward recurring training, credentialing and program-based offerings; the expected benefits of the ILETSB certification of the BolaWrap® 150 CIT Rescue Tool Level 1 Law Enforcement User Course, including whether and to what extent agencies will adopt the course or apply it toward mandated training requirements; the Company’s pending and planned curriculum submissions in other states; the development, scalability and expected benefits of the WrapTactics™ Learning Management System and the Company’s hybrid digital and in-person training model; the development of the Company’s instructor credentialing network and additional credential levels; the development, timing, and expected benefits of subscription-based and recurring-revenue programs and technology services; the Company’s approach of delivering Non-Lethal Response™ as an integrated program of technology, training, and ongoing customer support; the scaling of BolaWrap® deployments, customer onboarding, training, certification, and support; the Company’s strategy of scaling its core Non-Lethal Response business while develop`ing next-generation WrapShield technologies, capabilities, and partnerships; the size of the Company’s market opportunity and the demand of law enforcement agencies for the Company’s offerings; and the anticipated adoption of the Company’s products, training, and technologies by law enforcement, public safety, and national-security agencies. These statements are based on current expectations and assumptions and are subject to risks and uncertainties, including but not limited to the Company’s ability to integrate new leadership and realize the anticipated benefits of its organizational changes; the pace of customer and agency adoption; the Company’s ability to execute its transition toward subscription-based and recurring-revenue programs; changes in law enforcement budgets, policies, procurement practices, and use-of-force standards; the availability and terms of technology and training partnerships, including the Company’s ability to maintain its license with Frenel Imaging Ltd.; the Company’s ability to develop, achieve commercial readiness for, manufacture, sell, and support its products, training solutions, and emerging technologies, including the difference between development-stage initiatives and commercially available products; supply-chain and manufacturing constraints; competitive conditions; the Company’s ability to attract and retain qualified personnel; general economic and market conditions; and changes in law, regulation, or agency policy. ATF Ruling 2026-2 addresses the classification of the BolaWrap® 150 only, and no assurance can be given that any similar classification will apply to WrapShield, counter-unmanned aircraft systems, or any other product. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including the risk factors described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and other filings with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this release and are based on current expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, WRAP undertakes no obligation to update or revise any forward-looking statement.

Investor Relations Contact

(800) 583-2652 | ir@wrap.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2738daef-a9aa-40a9-ad19-8a67058dfc55

Among the first U.S. retail brokerages to offer Binary Return Options at launch, Moomoo continues to expand its options offering with innovative products designed to broaden investor choice and make options trading more accessible

JERSEY CITY, N.J., Nov. 11, 2026 (GLOBE NEWSWIRE) — Moomoo, a global investment and trading platform trusted by more than 31 million users* worldwide, today announced plans to join NYSE American in bringing Binary Return Options to U.S. retail investors. As one of the first U.S. retail brokerages to offer the exchange-listed options contracts at launch, Moomoo aims to bring this new options** product to investors from day one, broadening access to alternative ways of expressing market views through defined-outcome contracts on selected highly liquid stocks and ETFs.

Expanding Access to Innovative Options Products

Binary Return Options offer investors a more intuitive way to express directional views on whether a stock or ETF will finish above or below a specified price at expiration. Unlike traditional options, these European-style contracts feature an all-or-nothing payout structure, with a fixed return when the specified price condition is met.

Key features of Binary Return Options include:

• Two defined outcomes: Investors can choose between Finish High and Finish Low contracts, depending on whether they expect the underlying security to close at or above, or below, a specified strike price at expiration.
• Fixed Payout and Maximum Loss: Each contract pays $100 if the specified price condition is met, regardless of how far the underlying security moves beyond the strike price. If the condition is not met, the contract expires worthless, and buyers lose the premium paid. Actual returns depend on the premium and applicable fees.
• Underlying Securities and Expirations: The initial lineup spans 12 underlying securities — six individual equities (AAPL, AMZN, NVDA, ORCL, SPCX and TSLA) and six ETFs (GLD, IBIT, IWM, SLV, SPY and TLT) — with five consecutive weekly expiration series listed simultaneously.

By introducing Binary Return Options, Moomoo offers investors another way to position around key market catalysts, such as economic announcements and corporate earnings, or manage existing market exposure.

“We’ve seen this incredible growth in the US options market over the last several years. When we look inside that volume growth, there’s a lot of interest in newer ways to trade or newer products to trade,” said ⁠Kevin Tyrrell, Chief Product Officer at NYSE. “We are excited to see Moomoo offering these products to the U.S. Retail clients.”

Powering Smarter Options Trading

To support Binary Return Options trading, Moomoo offers investors dedicated risk analytics and visualized probability models, alongside its Advanced Order types and analytical tools such as P&L Simulator and Strategy Builder. Leveraging Moomoo’s fintech capabilities and advanced Super Intelligence, these tools help investors evaluate potential outcomes, assess volatility, manage risk and access institutional-grade market insights to make more informed trading decisions.

“We believe the next chapter of options trading should make it easier for investors to translate a market view into a trade, with a clear understanding of how the product works and what is at stake,” said Neil McDonald, CEO at Moomoo U.S. “Binary Return Options offer another way to make that possible. But our ambition goes beyond providing access to new products. It is about bringing together the trading experience, market insights and education that enable investors to make informed decisions and understand the risks behind them.”

Pioneering New Options Opportunities Globally

Leveraging its parent company’s global trading infrastructure and technology capabilities, Moomoo is bringing Binary Return Options to U.S. investors at launch, with plans to expand the product’s availability to Asia investors over time.

The launch marks another step in Moomoo’s broader efforts to advance its global options offering through product innovation, expanding the range of trading choices available to investors across markets. By combining a more diverse product lineup with professional-grade tools, AI-powered insights and investor education, Moomoo aims to make sophisticated market opportunities more accessible while empowering investors to make smarter decisions aligned with their individual strategies and risk appetites.

*Users of Moomoo Technologies Inc. and its affiliates as of 6/30/2026

**Options trading entails significant risk and is not appropriate for all investors. Read the Options Disclosure Document (ODD) at j.moomoo.com/017y9J before trading.

***Use of options strategies depends on account eligibility and approval level. Not all investors qualify for all strategies. Understand risks before trading.

Featured tools are available to Moomoo Engine members only. Moomoo Engine is a paid subscription ($3.99/mo or $39.90/yr; auto-renews). Subscription fee automatically reduces to $0.99/mo when account assets exceed $1,000 at the time of billing. Available to eligible Moomoo Financial Inc. (“MFI”) brokerage account holders. Rates and features are subject to change. Other terms and conditions apply. Investing is risky

Important Information: Before investing in an ETF, you should read both its summary prospectus and its full prospectus, which provide detailed information on the ETF’s investment objective, principal investment strategies, risks, costs, and historical performance (if any). You can find prospectuses on the websites of the financial firms that sponsor a particular ETF, as well as through your broker.

A Word About Risk: Investment returns will fluctuate and are subject to market volatility, so that an investor’s shares, when redeemed or sold, may be worth more or less than their original cost. ETFs are subject to market volatility and the risks of their underlying securities, which may include the risks associated with investing in smaller companies, international securities, commodities, fixed income, and more. An ETF may trade at a premium or discount to its net asset value (NAV).

About Moomoo

Moomoo is a leading global investment and trading platform dedicated to empowering investors with user-friendly tools, data, and insights. Our platform is designed to provide essential information and technology, enabling users to make well-informed investment decisions. With advanced charting tools, pro-level analytical features, Moomoo evolves alongside our users, fostering a dynamic community where investors can share, learn, and grow together.

Founded in the US, Moomoo has expanded its global presence to serve investors across multiple markets, including Singapore, Australia, Japan, Canada, Malaysia, and New Zealand. As a subsidiary of a Nasdaq-listed company, Moomoo is trusted by more than 31 million traders worldwide and has earned recognition from leading financial institutions and publications for its innovation and reliability, including being recognized as the #1 Broker for Stocks in North America in 2024 and 2025 by TradingView. Investing involves risk and the potential to lose principal. Securities offered through Moomoo Financial Inc., Member FINRA/SIPC.

For more information, please visit Moomoo’s official website at www.moomoo.com

Accolades are not indicative of future performance. Moomoo Financial Inc. is not affiliated with TradingView.

For more information, please visit:
https://www.tradingview.com/blog/en/revealing-broker-awards-winners-2024-50143/
https://www.tradingview.com/blog/en/broker-awards-2025-winners-56493/

Media Contact:
Carlee Snyder
pr@us.moomoo.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/a672edf2-4db0-482e-84fe-8f4fda088d92
https://www.globenewswire.com/NewsRoom/AttachmentNg/9fe5b938-daf4-416b-983a-dde795dd0eff

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 11, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that studies have commenced with QIMA Life Sciences, a world leading preclinical dermatology CRO, marking the formal kick-off of the partnership announced on September 18, 2026. QIMA will evaluate CDT’s proprietary tapinarof combinations in vitiligo using human skin from both healthy donors and patients, generating data in the most physiologically relevant setting available at the preclinical stage. Evidence of activity in human tissue gives potential partners far greater confidence in clinical translation than conventional models.

Vitiligo affects approximately 0.5%-2.0% of the global population, with the global vitiligo drug market estimated at approximately US$2.6 billion in 2025 and projected to reach US$6.6 billion by 2030. Current treatments often prove intolerable for many patients, especially pediatric patients, leaving a significant unmet need for therapies that are both effective and well tolerated. Positive results will form the core of the licensing data package for CDT’s tapinarof combinations, supported by the Company’s solid form and method-of-use patents and Sarborg-led AI analysis. CDT’s strategy is to out-license the combinations to a partner to take them through to commercialisation.

For further information or to discuss potential partnership opportunities, please contact the Company at info@cdtequity.com.

About QIMA Life Sciences

QIMA Life Sciences is a contract research organization specializing in cellular and molecular pharmacology. It partners with pharmaceutical and biotechnology companies to advance research and accelerate drug development through tailored, science-driven solutions spanning early discovery through clinical development. By combining preclinical and clinical research and testing solutions with advanced AI-driven image analysis and digital data platforms, QIMA Life Sciences enables companies to generate the robust scientific evidence needed to bring innovative drugs to patients with confidence. www.qima-lifesciences.com

About CDT Equity Inc.

CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT’s future results of operations and financial position, CDT’s business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT’s control, you should not rely on these forward-looking statements as predictions of future events.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.

Investors
CDT Equity Inc.
Info@cdtequity.com